Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro

Background: Metabolic associated fatty liver disease (MAFLD), characterized by hepatic lipid accumulation and fatty degeneration, is intertwined with obesity and type 2 diabetes mellitus (T2DM). Empagliflozin is a sodium-glucose cotransporter-2 inhibitor that effectively lowers blood glucose, but it...

Full description

Bibliographic Details
Main Authors: Ting Li, Ting Fang, Linxin Xu, Xiangyang Liu, Xiaoyu Li, Mei Xue, Xiaochen Yu, Bei Sun, Liming Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Pharmacology
Subjects:
empagliflozin
autophagy
diabetes
metabolic associated fatty liver disease
lipid accumulation
ten-eleven translocation 2
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.622153/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.622153/full

Similar Items